Detectable Serum Cardiac Troponin T as a Marker of Poor Prognosis Among Patients With Chronic Precapillary Pulmonary Hypertension
Top Cited Papers
- 19 August 2003
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Circulation
- Vol. 108 (7) , 844-848
- https://doi.org/10.1161/01.cir.0000084544.54513.e2
Abstract
Background— Right ventricular failure is a leading cause of death in patients with chronic pulmonary hypertension (PH). We checked whether detection of cardiac troponin T (cTnT), a specific marker of myocyte injury, could be useful in prognostic stratification of those patients. Methods and Results— Initial evaluation of 56 clinically stable patients (age 41±15 years) with pulmonary arterial (51 patients) or inoperable chronic thromboembolic (5 patients) PH (mean pulmonary arterial pressure 60±18 mm Hg) included cTnT test, allowing detection of its serum levels ≥0.01 ng/mL [cTnT(+)]. cTnT was detectable in 8 of 56 (14%) patients (mean±SD, 0.034±0.022; range, 0.010 to 0.077 ng/mL). Despite similar pulmonary hemodynamics, they had higher heart rate (92±15 versus 76±14 bpm, P=0.004), lower mixed venous oxygen saturation (50±10% versus 57±9%, P=0.04), and higher serum N-terminal pro-B–type natriuretic peptide (4528±3170 versus 2054±2168 pg/mL, P=0.03) and walked less during the 6-minute walk test (298±132 versus 396±101 m, P=0.02). Cumulative survival estimated by Kaplan-Meier curves was significantly worse at 24 months in cTnT(+) compared with cTnT(−) (29% versus 81%, respectively, log-rank test P=0.001). Multivariate analysis revealed cTnT status (hazard ratio, 4.89; 95% CI, 1.18 to 20.29; P=0.03), 6-minute walk test (hazard ratio, 0.93 for each 10 m; P=0.01), and pulmonary vascular resistance (hazard ratio, 1.13; P=0.01) as independent markers of mortality. All 3 cTnT(+) patients who survived the follow-up period converted to cTnT(−) during treatment. Conclusions— Detectable cTnT is a so-far ignored independent marker of increased mortality risk in patients with chronic precapillary PH, supporting the role of progressive myocyte injury in the vicious circle leading to hemodynamic destabilization.Keywords
This publication has 24 references indexed in Scilit:
- Survival in Primary Pulmonary HypertensionCirculation, 2002
- Long-term intravenous epoprostenol infusion in primary pulmonary hypertensionJournal of the American College of Cardiology, 2002
- Assessment of Survival in Patients With Primary Pulmonary HypertensionCirculation, 2002
- Decision Making with Cardiac Troponin TestsNew England Journal of Medicine, 2002
- CLINICAL CLASSIFICATION OF PULMONARY HYPERTERNSIONClinics in Chest Medicine, 2001
- MEDICAL THERAPY OF PULMONARY HYPERTENSIONClinics in Chest Medicine, 2001
- Frequency and prognostic significance of pericardial effusion in primary pulmonary hypertensionThe American Journal of Cardiology, 1999
- Prognoses of Primary Pulmonary Hypertension and Chronic Majorvessel Thromboembolic Pulmonary Hypertension Determined from Cumulative Survival Curves.Internal Medicine, 1999
- Immunoreactive amino‐terminal pro‐brain natriuretic peptide (NT‐PROBNP): a new marker of cardiac impairmentClinical Endocrinology, 1997
- Effects of Long-term Infusion of Prostacyclin (Epoprostenol) on Echocardiographic Measures of Right Ventricular Structure and Function in Primary Pulmonary HypertensionCirculation, 1997